City of Hope patient and lymphoma survivor Ted Schwartz made a $15 million donation to City of Hope on behalf of his family to advance immunotherapy research. This donation will only be used to accelerate immunotherapy research and therapeutic innovation, including the chimeric antigen receptor (CAR) T-cell therapy that saved his life.
Schwartz, who endured a 16-year battle with lymphoma but is now cancer-free following CAR T-cell therapy at City of Hope, offers better outcomes and quality of life for people living with cancer A global leader in CAR T cell therapy, City of Hope has built one of the most comprehensive CAR T clinical research programs in the world.
Immediate and long term support
Donations from the Schwartz family will be used to establish two foundations in the City of Hope. One is the Immunotherapy Accelerator Fund to provide immediate assistance to City of Hope’s Immunotherapy Team and the other is the Immunotherapy Research Endowment Fund. New potential therapies for decades to come.
Mr. Schwartz paid tribute to the City of Hope team and his trusted physician and friend Stephen Rosen, M.D., City of Hope Chancellor and Chief Scientific Officer, Morgan & Helen Chu, Director’s Chairs of the Beckmann Institute. I gave it as a gift. Research funding with core committees.
“The CAR T treatment I received in City of Hope finally helped me beat my lymphoma after a long 16-year battle that included multiple rounds of chemotherapy and radiation. I am an early beneficiary of advances in therapy and hope that research advances so more people can experience remission sooner. We offer this gift in honor of Dr. Rosen, who, along with his colleagues at the City of Hope, treats all patients with the utmost dignity and care, providing world-class CAR T and other We continue to lead advances in advanced treatments and help others avoid some of the difficulties and side effects associated with some current therapies, which have experienced longer-term remissions. I have.”
In gratitude for Schwartz’s gift, City of Hope is naming a planned 1.65-acre park in honor of the Schwartz family. The Ted Schwartz Family Hope and Healing Park will open in his 2024 on the City of Hope’s Los Angeles campus, providing a peaceful space for patients and visitors.
Leader in CAR T cell therapy
As a pioneer in CAR T-cell therapy, City of Hope is transforming cancer by applying its proprietary CAR T-cell technology to clinical and preclinical programs to address some of the most difficult-to-treat cancers. We are accelerating our clinical research approach. City of Hope has conducted more than 70 His CAR T and other immune effector cell trials, and to date, approximately 1,000 patients have participated in these trials or have received Food and Drug Administration-approved His CAR I am being treated with T cell therapy. Due to City of Hope’s longstanding expertise in delivering CAR T therapies, most of his CAR T treatments currently performed at City of Hope are delivered in an outpatient setting.
“I am an early beneficiary of this exciting advance in immunotherapy, and I hope that research advances so that more people experience remission sooner.”
Ted Schwartz, Donner
“A century of patient-centric, cutting-edge research has positioned the City of Hope at the forefront of breakthrough discoveries in CAR T-cell therapy. We are now the largest CAR T-cell program in the world. CAR T therapy holds great promise for so many patients like Ted, who are battling difficult-to-treat cancers,” said Rosen. “This gift from the Schwartz family will allow the City of Hope lab to continue promising immunotherapy research and provide meaningful options for patients in need of more targeted, life-saving treatments.”
harness the immune system
Immunotherapy harnesses the power of the patient’s own immune system to recognize and fight cancer, often with fewer side effects and more lasting results than surgery, chemotherapy or radiation therapy. . CAR T-cell therapy is a powerful immunotherapy. CAR T-cell therapy harvests immune cells from a patient’s bloodstream, reprograms the cells to recognize and attack specific proteins found on cancer cells, and reintroduces them into the patient’s system. , works by allowing targeted tumor cells to be destroyed.
Elizabeth Budde, MD, Ph.D., executive medical director of Enterprise Immune at City of Hope, said: Effector cell therapy program.
“City of Hope is at the forefront of developing personalized treatments that create hope like never before. Ted knows firsthand that cancer patients cannot afford to wait.”
Christine Bartel, Chief Philanthropy Officer, City of Hope
“City of Hope is at the forefront of developing personalized treatments that create hope never before possible, and Ted knows firsthand that cancer patients cannot afford to wait. It will play an important role in accelerating the development of new cancer treatments and cures,” said Kristin Bertell, Chief Philanthropic Officer of City of Hope. “We are extremely grateful for the courage, resilience and incredible generosity of Ted and his family, which has enabled us to provide life-saving care more quickly to those in need.”
